Citadel AI Fully Deploys AI Governance Tool at Ono Pharmaceutical, a First in the Pharma Industry, Supporting Safe and Secure Business Reform via Generative AI
Citadel AI's AI governance tool 'Citadel Lens' has been fully adopted by Ono Pharmaceutical, marking the first such deployment in the pharmaceutical industry to ensure safe use of generative AI.
📋 Article Processing Timeline
- 📰 Published: March 30, 2026 at 19:00
- 🔍 Collected: March 30, 2026 at 22:56 (3h 56m after Published)
- 🤖 AI Analyzed: April 22, 2026 at 05:55 (534h 59m after Collected)
Citadel AI Inc. (Representative Director: Hironobu Kobayashi, hereinafter "Citadel AI"), which provides AI governance tools that strengthen management capabilities in the generative AI era, announced that Ono Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, President and Representative Director: Toichi Takino, hereinafter "Ono Pharmaceutical") has fully adopted Citadel AI's AI governance tool "Citadel Lens" to improve the safety and reliability of generative AI utilization in internal operations.
Background of Deployment in the Pharmaceutical Industry
Corporate adoption of AI is now expanding across various departments, from the frontline to management. As AI is actively utilized, balancing "offense and defense"—how to defend against security and reputational risks—becomes extremely important.
Citadel AI provides Citadel Lens, an AI governance tool that realizes safe, secure, and "trustworthy AI" and promotes AI utilization. Citadel Lens is a unique product that supports the entire generative AI lifecycle all-in-one, from risk assessment in the adoption phase to real-time guardrails in the operational phase.
Particularly in the pharmaceutical industry, a life-related sector, the confidentiality and accuracy of the information handled are extremely important. When adopting generative AI, managing risks such as errors in AI-generated answers (hallucinations), bias, and information security becomes a major challenge.
In recent years, competition and speed in creating innovative medicines and the technological development required for drug discovery have intensified. For pharmaceutical companies to continue contributing to society globally through drug creation, it is urgent to establish an environment, such as promoting business reform through digital transformation (DX) and formulating guidelines for the use of generative AI. Ono Pharmaceutical is one of the companies driving advanced DX initiatives in the pharmaceutical industry. This time, they evaluated the capabilities of Citadel Lens in the field of AI governance, leading to the full-scale implementation of the system.
Future Prospects
Citadel Lens is a tool that appropriately detects and controls risks (answer quality risks, security risks) in the input and output of generative AI applications.
Through the implementation of Citadel Lens at Ono Pharmaceutical, Citadel will provide a continuous quality verification process for the generative AI (such as business chatbots) used company-wide by Ono Pharmaceutical. This makes it possible not only to maintain and improve the accuracy of generative AI responses but also to detect and address unexpected risks early, supporting the creation of an environment where employees can utilize AI with peace of mind. In the future, with a view to applying AI governance to more advanced areas including drug discovery research and pharmaceutical development processes, we aim to strengthen AI governance as a platform supporting "Offensive and Defensive DX."
Junyoshi Iseki, Head of IT I&O Dept., Digital Technology Division, Ono Pharmaceutical Co., Ltd.
In our company, we position the utilization of digital technologies, including generative AI, as a vital key to strengthening competitiveness. As a company involved in medicine and pharmaceuticals, we believe ensuring the safety and reliability of digital technology is crucial. With the introduction of Citadel Lens, we expect to automate AI risk assessments that previously required significant time and manual labor, thereby establishing a system that can drive innovation with a sense of speed.
Background of Deployment in the Pharmaceutical Industry
Corporate adoption of AI is now expanding across various departments, from the frontline to management. As AI is actively utilized, balancing "offense and defense"—how to defend against security and reputational risks—becomes extremely important.
Citadel AI provides Citadel Lens, an AI governance tool that realizes safe, secure, and "trustworthy AI" and promotes AI utilization. Citadel Lens is a unique product that supports the entire generative AI lifecycle all-in-one, from risk assessment in the adoption phase to real-time guardrails in the operational phase.
Particularly in the pharmaceutical industry, a life-related sector, the confidentiality and accuracy of the information handled are extremely important. When adopting generative AI, managing risks such as errors in AI-generated answers (hallucinations), bias, and information security becomes a major challenge.
In recent years, competition and speed in creating innovative medicines and the technological development required for drug discovery have intensified. For pharmaceutical companies to continue contributing to society globally through drug creation, it is urgent to establish an environment, such as promoting business reform through digital transformation (DX) and formulating guidelines for the use of generative AI. Ono Pharmaceutical is one of the companies driving advanced DX initiatives in the pharmaceutical industry. This time, they evaluated the capabilities of Citadel Lens in the field of AI governance, leading to the full-scale implementation of the system.
Future Prospects
Citadel Lens is a tool that appropriately detects and controls risks (answer quality risks, security risks) in the input and output of generative AI applications.
Through the implementation of Citadel Lens at Ono Pharmaceutical, Citadel will provide a continuous quality verification process for the generative AI (such as business chatbots) used company-wide by Ono Pharmaceutical. This makes it possible not only to maintain and improve the accuracy of generative AI responses but also to detect and address unexpected risks early, supporting the creation of an environment where employees can utilize AI with peace of mind. In the future, with a view to applying AI governance to more advanced areas including drug discovery research and pharmaceutical development processes, we aim to strengthen AI governance as a platform supporting "Offensive and Defensive DX."
Junyoshi Iseki, Head of IT I&O Dept., Digital Technology Division, Ono Pharmaceutical Co., Ltd.
In our company, we position the utilization of digital technologies, including generative AI, as a vital key to strengthening competitiveness. As a company involved in medicine and pharmaceuticals, we believe ensuring the safety and reliability of digital technology is crucial. With the introduction of Citadel Lens, we expect to automate AI risk assessments that previously required significant time and manual labor, thereby establishing a system that can drive innovation with a sense of speed.